Compugen (CGEN) Q2 2026: Revenue Doubles Estimates on Gilead Milestone
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Compugen doubled revenue expectations on Gilead milestone payments, extending cash runway into 2029 while awaiting a potential make-or-break clinical readout on COM701 in early 2027.
Continue ReadingShow less
Compugen reported Q2 2026 revenue of $2.6 million, more than doubling the consensus estimate of roughly $1.28 million — a beat of about 103%. The outperformance was driven by milestone payments from its Gilead partnership rather than product sales, which is a meaningful distinction: milestone-based revenue can be lumpy and does not necessarily signal accelerating commercial momentum. That lumpiness is visible in the trailing revenue chart, where Q4 2025 spiked to $67.3 million before falling back sharply.
On the bottom line, Compugen posted a loss of $0.07 per share against an estimated loss of $0.085, beating by about 18%. The stronger cash picture that comes with the Gilead payments has pushed the company's projected cash runway out to 2029, giving management more room to maneuver without an immediate need for dilutive financing.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The date that matters most on the calendar is now early 2027, when clinical data for COM701 — Compugen's lead pipeline asset — is expected. That readout is widely viewed as a make-or-break moment for the company's longer-term story, and the extended runway means investors will not be waiting under the pressure of an imminent funding cliff.
Mentioned: CGEN